41st week of 2008 patent applcation highlights part 43 |
Patent application number | Title | Published |
20080249002 | CYCLOSPORIN ALKYNE ANALOGUES AND THEIR PHARMACEUTICAL USES - The compounds of the present invention are represented by the chemical structure found in Formula I: | 2008-10-09 |
20080249003 | Compounds Inhibiting the Binding of Sap for Treating Osteoarthritis - Use of an agent capable of inhibiting SAP ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject. | 2008-10-09 |
20080249004 | Method of Modulating Cell Survival, Differentiation and/or Synaptic Plasticity - The present invention relates to a method of modulating differentiation, adhesion and/or survival of the neural cell adhesion molecule (NCAM) presenting cells by providing compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM. The invention provides candidate compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM by using methods for screening and testing described in the application. The invention further relates to pharmaceutical compositions comprising compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM and to use of the pharmaceutical compositions and compounds for the modulation of differentiation, adhesion and/or survival of NCAM presenting cells. | 2008-10-09 |
20080249005 | Use of Dm43 and Its Fragments as Matrix Metalloproteinases Inhibitor - This invention is related to the use of DM43 protein as a metalloproteinases inhibitor. More specifically, this invention is related to the use of DM43 for the therapeutics of pathologies such as cancer and osteoarthritis, which are dependent on matrix metalloproteinases inhibition, based on the structure identity with SVMPs. | 2008-10-09 |
20080249006 | Pharmaceutical Preparation for the Treatment of Shock - The invention relates to the use of a peptide of general Formula I | 2008-10-09 |
20080249007 | Protracted Exendin-4 Compounds - Novel protracted exendin-4 compounds and therapeutic uses thereof. | 2008-10-09 |
20080249008 | Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor - The present invention is based, in part, on our discovery that EGF can be engineered to generate mutants that bind to the EGF receptor (EGFR) of a cell and that have a desirable effect on the activity of the cell. For example, the mutants can agonize the receptor (i.e., increase a biological activity of the receptor), or antagonize the receptor (i.e., decrease or inhibit a biological activity of the receptor). In turn, the rate at which the cell proliferates, for example, can be changed. Moreover, some of these mutants bind EGFR with a higher affinity than wild-type EGF exhibits. The affinity may increase by about, for example, 2-, 5-, 10-, 15-, 20-, 25-, 30-, 50-, or 100-fold relative to wild-type EGF. | 2008-10-09 |
20080249009 | Lipoprotein-Regulating Medicaments - Methods and pharmaceutical compositions useful for treating obesity-related disorders using ApM-1 and related proteins. | 2008-10-09 |
20080249010 | Method Of Inducing Apoptosis In Lymphoid Cells - A two-stage, transcriptionally regulated apoptotic program has been discovered. In the first stage, IL-3 withdrawal results in transcriptional activation of the NGAL gene followed by synthesis and secretion of NGAL protein. In the second stage, secreted NGAL protein induces apoptosis in lymphoid cells by an autocrine mechanism. Based on this discovery, the invention provides a method of inducing apoptosis in a lymphoid cell in a mammal, e.g., a human patient. The invention includes administering a therapeutically effective amount of an NGAL polypeptide or NGAL-like polypeptide to a mammal. | 2008-10-09 |
20080249011 | Use of Mgc4504 - The invention concerns the use of MGC4504 protein, a functional derivative or fragment thereof, or a nucleic acid coding for said protein, derivative or fragment, for the identification of substances active in preventing or treating a disease associated with or caused by a malfunction of the carbohydrate or lipid metabolism. | 2008-10-09 |
20080249012 | INCREASING LIFE SPAN BY MODULATION OF Smek - The Smek (Suppressor of mek null) gene is described and characterized. Smek acts in the stress response pathway of animals by binding to and enhancing the transcription of FOXO, thereby providing the link between the stress response pathway and the insulin/IGF-1 pathway. Given the link between both the stress response pathway and the insulin/IGF-1 pathway and longevity, Smek | 2008-10-09 |
20080249013 | Vaccines - Compositions and methods for the therapy and diagnosis of cancer, particularly lung, colon, colorectal and breast cancer, are disclosed. Illustrative compositions comprise one or more Cripto tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung, colon, colorectal and breast cancer. | 2008-10-09 |
20080249014 | METHOD OF PURIFICATION OF HYDROPHOBIC PROTEINS - The present invention relates to a method for obtaining highly purified hydrophobic proteins from cells by extraction using a buffer containing a detergent and removal of said detergent by hydroxyapatite (HA) column chromatography. | 2008-10-09 |
20080249015 | Use of Des-Aspartate-Angiotensin 1 - The present invention generally relates to the use of des-aspartate-angiotensin I, its derivative, a functional part and/or analogue thereof in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I, its derivative, a functional part and/or analogue thereof, for the treatment and/or prophylaxis of viral infections, for inducing hypoglycaemia and/or for reducing hyperglycaemia, and/or for treatment of a hypoglycaemia-related condition. | 2008-10-09 |
20080249016 | Use of GLP-2 in a combination treatment for bone-related disorders - The present invention relates to methods of treatment of patients having an undesirably low bone mass or an undesirably high rate of bone resorption or an undesirably low rate of bone formation, which method comprises administering to the patient a therapeutically effective amount of each of:
| 2008-10-09 |
20080249017 | PHARMACEUTICAL FORMULATIONS OF GHRH MOLECULES - Stabilized solid and liquid pharmaceutical formulations comprising a GHRH molecules as active ingredient, and more particularly GHRH analogs including [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises an anionic surfactant and a non-reducing sugar, and has a pH of about 4.0 to about 7.5. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it. | 2008-10-09 |
20080249018 | Exendin Analog Formulations - Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided | 2008-10-09 |
20080249019 | TREATMENT OF MUCUS HYPERSECRETION - A polypeptide and a nucleic acid encoding the polypeptide are described. The polypeptide includes a cytotoxic toxin, a targeting domain that selectively binds to a target cell that is a mucus-secreting cell and a translocating domain that translocates the cytotoxic toxin into the target cell. A nucleic acid encoding the polypeptide is also described. Also described is a pharmaceutical composition for topical administration to a patient suffering from mucus hypersecretion which includes the polypeptide and a formulation component selected from the group consisting of an excipient, an adjuvant and a propellant. Methods of treating hypersecretion of mucus, chronic obstructive pulmonary disease (COPD) or asthma are also described. These methods include administering to a patient in need thereof a therapeutically effective amount of the polypeptide. | 2008-10-09 |
20080249020 | Human Growth Hormone Treatment Methods - New methods for developing dosing formulas that allow the determination of appropriate dosage regimens for human growth hormone (hGH) compounds; methods for using such formulas to calculate individualized hGH compound dosage regimens; methods for treatment of hGH-responsive syndromes in patients using such determined regimens; systems, devices, and computer-readable media comprising instructions for receiving predictive value information and for generating dosage regimens and/or dosing formulas; and other related systems and methods are provided by the invention described herein. | 2008-10-09 |
20080249021 | BIOLOGICALLY ACTIVE PEPTIDES AND THEIR USE FOR REPAIRING INJURED NERVES - The present invention relates to biologically active peptides derived from the neurite outgrowth-promoting domain of laminin-1, i.e. the γ1 -chain of laminin-1. These peptides include the decapeptide RDIAEIIKDI (SEQ ID NO:1) and the truncated peptides derived therefrom comprising the biologically active domain thereof, the tripeptide KDI. The invention is directed to the biologically active tripeptide motif KDI, and to its use in promoting regeneration of neuronal or non-neuronal tissues and, in specific, to its use in the treatment of spinal cord injuries. | 2008-10-09 |
20080249022 | Antimicrobial Peptides Derived From Cap18 - The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally. | 2008-10-09 |
20080249023 | Antibacterial Peptide with Activity Against B. Anthracis - Disclosed is a therapeutic peptide useful in the treatment or prevention of infection caused by Gram-positive bacteria such as | 2008-10-09 |
20080249024 | Peptides facilitating or inhibiting a nterograde transport - The present invention concerns amyloid precursor protein (APP)-based peptide sequences and their uses to facilitate or inhibit anterograde (synapse-directed) transport. The peptide sequences are of the formula GYENPTYX1X2X3X4X5X6X7X8 (SEQ ID NO: 13),
| 2008-10-09 |
20080249025 | Methods and Means For Inhibition of CDK4 Activity | 2008-10-09 |
20080249026 | PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING alpha3beta1 INTEGRINS - The present invention relates to a peptide comprising the sequence R | 2008-10-09 |
20080249027 | CHEC-7 a novel sPLA2 inhibitor and methods of use for treating neurological and inflammatory disorders - The present invention relates to the discovery of a composition including a seven-amino acid peptide that promotes neuronal survival, inhibits inflammation, and is a potent inhibitor of sPL2A, and uses thereof. | 2008-10-09 |
20080249028 | Thyrotropin-Releasing Hormone Analogs and Method of Use - The invention provides a method of modulating blood glucose levels by treating or preventing pancreas-related disorders with thyrotropin-releasing hormone (TRH) or a TRH derivative. Diabetes mellitus, pancreatic islet destruction, pancreatic beta cell malfunction, and hyperglycemia-related malfunction are preferably treated or prevented. | 2008-10-09 |
20080249029 | Methods for Treating Skin Pigmentation - This invention relates to methods and compositions for bringing about changes in skin pigmentation. More particularly, this invention relates to compounds which affect melanogenesis and can be used as depigmenting agents or as agents for darkening skin utilizing the PAR-2 pathway. | 2008-10-09 |
20080249030 | Age Inhibitors - The invention relates to a compound having general formula I, wherein: X represents CH | 2008-10-09 |
20080249031 | CRYSTALLINE FORMS - The present invention relates to crystalline forms of (3S)-3-[N—(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to pharmaceutical compositions comprising such crystalline forms and to the use of said pharmaceutical compositions and said crystalline forms in the treatment of various conditions, particularly in the treatment of liver fibrosis. | 2008-10-09 |
20080249032 | Derivatives of Arylsulfonamido-Substituted Hydroxamic Acid as Matrix Metalloproteinases Inhibitors - Described herein are derivatives of arylsulfonamido-substituted hydroxamic acid of formula (I) having good solubility in water and inhibitory activity of matrix metalloproteinases, useful for the preparation of pharmaceutical compositions for the treatment of diseases associated to a pathologic activity and/or an over-expression of metalloproteinases, and of cosmetic preparations having anti-ageing properties in particular for hair and skin. | 2008-10-09 |
20080249033 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections - The present invention relates to 14- or 15-membered macrolides substituted at the 4″ position of formula (I) | 2008-10-09 |
20080249034 | Use of Macrolides for Treating Intestinal Inflammation - The present invention relates to a compound of formula (IA) as defined in the specification or a pharmaceutically acceptable sat thereof, in the preparation of a medicament for both the treatment of inflammatory bowel diseases and the prevention of colon cancer. | 2008-10-09 |
20080249035 | Polymorph of Clarithromycin (Form V) - A polymorphic form of clarithromycin (form V) which exhibits a characteristic X-ray diffraction pattern, a method for producing such polymorphic clarithromycin, and the use of such polymorphic clarithromycin to treat bacterial infections. | 2008-10-09 |
20080249036 | Antagonist Against Tolerance to Anticancer Drugs - An ABC transporter protein expression inhibitor comprising, as the active ingredient(s), 0.001 to 100 nM of one or more members selected from among steroid hormones, compounds having a female hormone function, analogous compounds thereof and antagonistic inhibitors therefor; an anticancer composition containing this ABC transporter protein expression inhibitor and an anticancer drug; and cells useful in the development of an anticancer drug. The present invention provides a drug which inhibits the expression of an ABC transporter to thereby overcome resistance to anticancer drugs; cancer cells useful in screening such drugs; and an anticancer drug efficacious even against such a cancer as having acquired resistance to anticancer drugs. | 2008-10-09 |
20080249037 | Synthetic Molecules Having Immune Activity - The present invention is directed to synthetic molecules having biological activity similar to PIM (acyl glycerol phosphatidylinositol manno-oligosacccharide) activity, for use in the treatment and prevention of inflammatory or immune cell mediated diseases or disorders. | 2008-10-09 |
20080249038 | Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof - The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an active ingredient a BMP2A inhibitor further comprising a pharmaceutically acceptable diluent or carrier. An additional embodiment provides a method for reducing damage to the central nervous system in a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition in a dosage sufficient to reduce the damage. Yet another embodiment provides of the use of a BMP2A inhibitor for the preparation of a medicament for promoting or enhancing recovery in a patient who has suffered an injury to the central nervous system. Preferable inhibitors according to some embodiments of the invention are siRNA molecules and neutralizing antibodies. An additional embodiment provides a method for identifying a chemical compound that modulates apoptosis. Further, a process for diagnosing a neurodegenerative disease or an ischemic event in a subject is provided. The preferred methods, materials, and examples that will now be described are illustrative only and are not intended to be limiting; materials and methods similar or equivalent to those described herein can be used in practice or testing of the invention. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims. | 2008-10-09 |
20080249039 | Modified Short Interfering Rna (Modified Sirna) - The present invention is directed to modified siRNA which are significantly impaired in their ability to support cleavage of mRNA when incorporated into a RISC complex. Such modified siRNA may be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the modified siRNA comprises a sense strand and an antisense strand, wherein the sense strand contains a modified RNA nucleotide in at least one of positions 8-14, calculated from the 5′-end. | 2008-10-09 |
20080249040 | RNA interference mediated inhibition of sterol regulatory element binding protein 1 (SREBP1) gene expression using short interfering nucleic acid (siNA) - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of Sterol Regulatory Element-Binding Protein 1 (SREBP1) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in Sterol Regulatory Element-Binding Protein 1 (SREBP1) gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against Sterol Regulatory Element-Binding Protein 1 (SREBP1) gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, and others that can inhibit the function of endogenous RNA molecules, such as endogenous micro-RNA (miRNA) (e.g, miRNA inhibitors) or endogenous short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate SREBP1 gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC), including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules and are useful, for example, in providing compositions to prevent, inhibit, or reduce metabolic diseases traits and conditions, including but not limited to hyperlipidemia, hypercholesterolemia, cardiovascular disease, atherosclerosis, hypertension, diabetis (e.g., type I and/or type II diabetis), insulin resistance, obesity and/or other disease states, conditions, or traits associated with SREBP1 gene expression or activity in a subject or organism. | 2008-10-09 |
20080249041 | Formulations comprising antisense nucleotides to connexins - A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening. | 2008-10-09 |
20080249042 | All-Trans-Retinol: All-Trans-13,14-Dihydroretinol Saturase and Methods of Its Use - Compositions of all-trans-retinol: all-trans-13,14-dihydroretinal saturase and methods of use thereof are provided. | 2008-10-09 |
20080249043 | Methods and Compositions Involving Protein Kinase C-Delta - Disclosed are methods and compositions relating to the use of PKC-δ activators in the treatment of disease. | 2008-10-09 |
20080249044 | Nucleic acid external skin formulation - The present invention provides a nucleic acid external skin formulation having high skin permeability, which is prepared from a polymeric nucleic acid which has high molecular weight and sodium alginate. The nucleic acid external skin formulation is highly skin permeable and delivers its active ingredient nucleic acid to the affected area efficiently. The nucleic acid used may be smaller in amount, and thus, the formulation is also superior in safety and cost. The working mechanism thereof is different from that of the low-molecular weight compounds currently used as an active ingredient for skin anti-inflammatory agents, and thus, the formulation may be applicable to cases where such low-molecular weight medicines are less effective. | 2008-10-09 |
20080249045 | MGAL: A GAL Gene Switch-Based Suite of Methods for Protein Analyses and Protein Expression in Multicellular Organisms and Cells Therefrom - The invention provides methods for detecting and analyzing protein-protein interactions and agonists and antagonists thereof, detecting and analyzing protein sequences, and regulatable gene expression in multicellular organisms or cells therefrom. | 2008-10-09 |
20080249046 | MODIFIED siRNA MOLECULES AND USES THEREOF - The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains full RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided. | 2008-10-09 |
20080249047 | Modulation of Inflammation Through Modulation of Elavl1/HuR Expression - In the present invention modulation of expression of a member of the Elavl1/Hu family is used to modulate at least translation of specific mRNA. Inducible increase of HuR in murine innate compartments suppresses inflammatory responses in vivo. HuR over-expression induced the translational silencing of specific cytokine mRNAs, despite positive or nominal effects on their corresponding turnover. The present invention uses the fact that HuR acts in a pleiotropic fashion in inflammation through its functional interactions with specific mRNA subsets and negative posttransciptional modules. | 2008-10-09 |
20080249048 | Methods and Compositions for the Treatment of Intestinal Conditions - Methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease, are disclosed. Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds. | 2008-10-09 |
20080249049 | Polycationically Charged Polymer and the Use of the Same as a Carrier for Nucleic Acid - A composition for the delivery of nucleic acid to target cells or tissues, which comprises polycationically charged polymer as a carrier of nucleic acid is provided. Said polycationically charged polymer is a polymer which may comprise a charged polymer segment having a main chain based on poly(amino acid), polysaccharide, polyester, polyether, polyurethane or vinyl polymer and having, as a side chain, a group of formula —NH—(CH | 2008-10-09 |
20080249050 | Compounds and methods to enhance rAAV transduction - Agents and methods to alter rAAV transduction are provided. | 2008-10-09 |
20080249051 | Antimicrobial Compounds - The present invention relates to compounds that modulate the shikimate pathway and/or a pathway branching from the shikimate pathway in members of the Amoebida Order. In particular these compounds may be useful in the treatment or prevention of diseases caused or contributed to by members of the Amoebida Order. | 2008-10-09 |
20080249052 | Synthetic mini/micro-dystrophin genes to restore nNOS to the sarcolemma - The present invention provides novel dystrophin mini/micro-genes that retain the essential biological functions of a full-length dystrophin gene. More particularly, the present invention provides to a series of synthetic mini/micro-dystrophin genes capable of restoring neuronal nitric oxide synthase (nNOS) to the sarcolemma. A method as well as a pharmaceutical composition for treatment of Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), and X-linked Dilated Cardiomyopathy (XLDC) are also provided. | 2008-10-09 |
20080249053 | Compositions And Methods For Detecting And Treating Neurological Conditions - The present invention relates to the NIPA-1 proteins and nucleic acids encoding the NIPA-1 proteins. The present invention further provides assays for the detection of NIPA-1 polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NIPA-1 proteins. | 2008-10-09 |
20080249054 | METHOD OF MEASURING LIPID DROPLETS AND APPLICATIONS OF USING THE SAME - The invention relates to methods of screening agents for the ability to regulate lipid metabolism and using said agents to treat diseases or disorders related to lipid metabolism (e.g., obesity, diabetes [non-insulin and insulin dependent], hypertension, coronary artery disease, hyperlipidemia (e.g., LDL, TAGs), hypolipidemia (e.g., HDL), lipid metabolism disorders, lipid deposition disorders, lipodystrophies). In specific embodiments, the invention relates to using a PAT family protein to screen agents for the ability to regulate lipid metabolism and using the same to treat diseases or disorders related to lipid metabolism. In further embodiments, the invention relates to high throughput screening (HTS) methods that can be used in the drug discovery process for screening agents for the ability to regulate lipid metabolism. | 2008-10-09 |
20080249055 | Use of Seh Inhibitors as Analgesics - The present invention provides methods and compositions for relieving pain and itching, of promoting wound healing, of reducing sickness behavior and of reducing inflammatory bowel disease or acne lesions in a subject by the topical administration of an inhibitor of soluble epoxide hydrolase, or of a cis-epoxyeicosatrienoic acid (“EET”), or by both. | 2008-10-09 |
20080249056 | Methods of Altering an Immune Response Induced by Cpg Oligodeoxynucleotides - It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D ODN. Methods of decreasing an immune response to a CpG ODN are also disclosed. These methods include administering an agent that decreases the activity and/or expression of CXCL16. Compositions including one or more D-type ODNs and an agent that modulates that activity and/or expression of CXCL16 are provided. | 2008-10-09 |
20080249057 | Protein kinase C as a target for the treatment of respiratory syncytial virus - The subject invention concerns a method of inhibiting respiratory syncytial virus (RSV) infection in a patient by decreasing the endogenous protein kinase C (PKC) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administration of a PKC inhibitor. The present inventor has determined that decreasing normal endogenous PKC activity is inhibitory to RSV infection of human cells. The subject invention also pertains to pharmaceutical compositions containing a PKC inhibitor and a pharmaceutically acceptable carrier. | 2008-10-09 |
20080249058 | AGENTS THAT REDUCE NEURONAL OVEREXCITATION - The present invention provides methods of identifying candidate agents for treating excitotoxicity-related disorders. The present invention further provides methods for treating excitotoxicity-related disorders. | 2008-10-09 |
20080249059 | Compositions and Methods for modulating Calcium Flux, Glucose Homeostasis and Apoptosis - Compositions and methods are disclosed which are effective for modulating glucose homeostasis, calcium ion flux and cell death in target cells. | 2008-10-09 |
20080249060 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION - Disclosed are compounds, compositions and methods for treating hepatitis C virus infections. | 2008-10-09 |
20080249061 | Photostable Pharmaceutical Composition Containing Brivudine for the Treatment of Herpetic Keratitis - Ophthalmic composition containing brivudine as active ingredient and a film-forming agent selected from the group consisting of polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA) and polyacrylate (PA). | 2008-10-09 |
20080249062 | Nucleus Pulposus Filler - The present invention provides a nucleus pulposus filler or the like which is to be packed into an area in deformed intervertebral disc wherein normal nucleus should be located and can be stabley maintained for a long time. More preferably, the present invention provides a nucleus pulposus filler comprising a crosslinked chondroitin sulfate as an active ingredient. The photocrosslinked chondroitin sulfate is preferably the following one: a photocrosslinked chondroitin sulfate obtainable by freezing a photoreactive chondroitin sulfate-containing solution comprising: a photoreactive chondroitin sulfate to which a photoreactive group is bound; an aqueous solvent capable of dissolving the photoreactive chondroitin sulfate; and any one substance selected from the group consisting of an alcohol having aqueous solvent miscibility, a surfactant, and a cheleting agent; irradiating the resulting frozen product with light; and then melting the frozen product. The filler can be provided as a kit by packing it into a container from which the filler can be pushed out. | 2008-10-09 |
20080249063 | Composition for promoting the maintenance and function of muscle-specific progenitor cells - The biological function of skeletal muscle precursor cells in the repair and growth of skeletal muscle in response to exercise is promoted by providing a supplemental composition comprising at least creatine and fucoidin to reinforce biochemical pathways involved in the maintenance of skeletal muscle satellite cells and other myogenic precursors. The composition and method of the present invention induce muscle hypertrophy via satellite cells fusion to muscle fibres and induce a substantially simultaneous replenishment of myogenic precursor cells in response to exercise in a mammal. | 2008-10-09 |
20080249064 | Activities of an active principle obtained from powdered alfalfa seeds (Medicago sativa), active principle used and process of obtaining the same - The object of the invention is an active principle derived from a powder of alfalfa seeds ( | 2008-10-09 |
20080249065 | Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate - This invention relates to ophthalmic wound-healing pharmaceutical compositions based on amino acids and sodium hyaluronate. | 2008-10-09 |
20080249066 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS - Described herein are compounds useful in the treatment of viral diseases, compositions comprising them and methods of using them. The compounds comprise a nucleoside or nucleoside analog linked, commonly through a phosphate group to one of a selected group of lipids. In some embodiments, the compounds described herein are useful for treating HIV infection, AIDS and other viral infections. | 2008-10-09 |
20080249067 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells - The present invention describes organophosphorus compounds of general formula (I) | 2008-10-09 |
20080249068 | Method of Extending the Dose Range of Vitamin D Compounds - Inhibitors of bone calcium resorption are administered, and calcium intake in the subject's diet is restricted, to allow high doses of vitamin D compounds or mimetics to be given with the intent of treating diseases such as metabolic bone diseases, hyperparathyroidism, cancer, psoriasis, and autoimmune diseases without the dangers of calcification of kidney, heart, and aorta. Inhibitors of bone calcium resorption include the bis-phosphonates, OPG (osteoprotegerin) or the soluble RANKL (receptor activator of NF-κB ligand) receptor known as sRANK (soluble RANK which is the protein expressed by the NF-κB gene), and function to block the availability of calcium from bone thereby preventing hypercalcemia and the resulting calcification of soft tissues. Thus, high doses of 1α,25-dihydroxyvitamin D | 2008-10-09 |
20080249069 | METHOD OF TREATMENT USING BISPHOSPHONIC ACID - The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month. | 2008-10-09 |
20080249070 | Cycloalkane-Containing Sphingosine 1-Phospate Agonists - The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P | 2008-10-09 |
20080249071 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR - A medicament having inhibitory activity against NF-κB activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: | 2008-10-09 |
20080249072 | Use of Low Dose Chemically Modified Tetracylines to Reduce Inflammatory Mediators - The invention is a method for reducing the production of inflammatory mediators, and/or treating conditions characterized by increased levels of inflammatory mediators, in a mammal in need thereof, by administering a 4-dedimethlaminosancycline to the mammal. | 2008-10-09 |
20080249073 | Skin Treatment Composition - This invention relates to a cosmetic composition comprising:
| 2008-10-09 |
20080249074 | Composition for the Transdermal Administration of Physiologically Active Agents - Improved composition for the administration of a physiologically active agent through the skin which comprises at least one vegetable oil, oleic acid, and at least one lactone of a saturated or unsaturated fatty acid of 5 to 22 carbon atoms, said two last components acting as absorption enhancers. Using said composition, unexpected increased values of the absorption of the physiologic active agent through the skin are obtained due to an unpredictable synergistic effect. | 2008-10-09 |
20080249075 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds - Retrosteroidal compounds corresponding to formula I, representing progesterone receptor modulators, and their production, and pharmaceutical preparations containing these compounds. These compounds are useful in the treatment of benign gynecological disorders such as endometriosis and uterine fibroids, as well as for female birth control and for hormone replacement therapy. | 2008-10-09 |
20080249076 | Pharmaceutical Compositions Comprising Danazol - A controlled release pharmaceutical comprising danazol has the property of slow release of danazol over an extended period of time and markedly increased bioavailability compared to commercially available danazol-containing products. The pharmaceutical composition comprises danazol dissolved in a solid vehicle or carrier and is especially suitable for oral solid dosage forms. The composition significantly reduces food effect and may reduce side effects. | 2008-10-09 |
20080249077 | 17.Beta.-Fluoromethoxycarbonyl-Androst-4-En-3-One Compounds With a 17.Alpha.-Carbonate Sustituent - The present invention is directed to compounds of formula (I): | 2008-10-09 |
20080249078 | Method and use of nanoparticles to bind biocides in paints - This invention relates to the use of a combination of selected substances in paint to prevent the settlement and growth of different biofouling organisms with a reduced negative effect on the ecosystems compared to present methods. | 2008-10-09 |
20080249079 | Pyrimidine Derivatives As Kinase Modulators and Method of Use -
The invention provides compounds and methods for inhibition of kinases, more specifically IGF 1 R kinases. The invention also provides compounds and methods for inhibition of wildtype Abl. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, V is NR | 2008-10-09 |
20080249080 | Benzodiazepine Derivatives and Uses Thereof on Medical Field - The invention concerns benzodiazepine derivatives of formula | 2008-10-09 |
20080249081 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR - Disclosed herein are benzoimidazole compounds; pharmaceutical compositions comprising a therapeutically effective amount of the same; methods of modulating the activity of an MrgX1 or an MrgX2 receptor using the same; and methods of alleviating acute, chronic and neuropathic pain in a subject using the same. Also disclosed are methods of identifying a benzoimidazole compound that modulates the activity of an MrgX1 or an MrgX2 receptor; methods of identifying a benzoimidazole compound effective for the treatment of pain. | 2008-10-09 |
20080249082 | Use of Memantine (Namenda) to Treat Autism, Compulsivity and Impulsivity - The present invention relates to the treatment of compulsive, impulsive and pervasive developmental disorders. More particularly, the methods described herein comprise administration of memantine to an individual suffering from such a disorder in an amount effective to relieve one or more symptoms of said disorder. In particularly preferred aspects, the invention is directed to the use of memantine for the treatment of autism | 2008-10-09 |
20080249083 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE - Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes. | 2008-10-09 |
20080249084 | Triazole Compounds and Uses Related Thereto - The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound is useful as a therapeutic drug for the treatment of diabetes, obesity or metabolic syndrome. | 2008-10-09 |
20080249085 | Maytansinoid Analogs as Antitumor Agents - Ansamycin analogs, including maytansinoid analogs, and their use in treating cell proliferative diseases and conditions, and in particular, for use as antitumor agents. | 2008-10-09 |
20080249086 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias -
There is provided compounds of formula I, wherein R | 2008-10-09 |
20080249087 | Heterocylic antiviral compounds - This invention relates to piperidine derivatives of formula I wherein R | 2008-10-09 |
20080249088 | Topical Delivery of Antifungal Drugs - A topical formula for treatment of antifungal infections of the skin and nails comprises: (a) a therapeutically effective amount of a benzylamine or morpholine antifungal compound; (b) an aliphatic alcohol substituted with an aromatic substituent in which the antifungal compound is soluble to a degree that a therapeutically effective concentration of the antifungal compound can be applied topically in solution; and (c) a distribution solvent or mixture of solvents in which the solvent mixture of parts (a) and (b) is soluble, and which has a boiling point that is less than about 110.degree.C. The benzylamine compound can be butenafine. The morpholine compound can be amorolfine. The aliphatic alcohol substituted with an aromatic substituent can be benzyl alcohol, or phenethyl alcohol. The distribution solvent mixture can include ethyl alcohol, water, or isopropyl alcohol. Alternatively, the formula can include a second antifungal compound. | 2008-10-09 |
20080249089 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS - The present invention relates to substituted xanthines of general formula | 2008-10-09 |
20080249090 | Substituted pyridone compounds and methods of use - The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I | 2008-10-09 |
20080249091 | Indoles Useful in the Treatment of Inflammation - There is provided compounds of formula I, | 2008-10-09 |
20080249092 | Novel Quinoline Compounds Capable Of Binding At The Cb2 Receptor - The present invention relates to novel quinoline derivatives such as compounds of the formula (I) which possess are capable of selectively modulating the cannabinoid 2 receptor: | 2008-10-09 |
20080249093 | (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists - The present invention encompasses compounds of Formula I: | 2008-10-09 |
20080249094 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS - The present invention relates to compounds of the Formula | 2008-10-09 |
20080249095 | 1-Acyldihydropyrazole Derivatives - Compounds of the formula (I), in which R | 2008-10-09 |
20080249096 | Pharmaceutical Forms with Improved Pharmacokinetic Properties - The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation. | 2008-10-09 |
20080249097 | PRODRUGS OF HETEROARYL COMPOUNDS - The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents. | 2008-10-09 |
20080249098 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide Derivatives, Their Preparation and Therapeutic Use - A subject-matter of the invention is the compounds of general formula (I) | 2008-10-09 |
20080249099 | 7-Phenylalkyl Substituted 2-Quinolinones and 2-Quinoxalinones as Poly(Adp-Ribose) Polymerase Inhibitors - The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) | 2008-10-09 |
20080249100 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses pteridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: | 2008-10-09 |
20080249101 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES - This invention relates to compounds of the formula | 2008-10-09 |